Shares of Cresco Labs surged to $0.72, up 7.1% from the prior close, as traders piled in ahead of the company's second-quarter 2026 earnings report scheduled for August 6 — a classic pre-earnings positioning play amplified by a broad risk-on day across U.S. markets. Cresco Labs Beats Estimates and Swings to Profit, but at $0.72 a Share, Is the Market Still Sleeping on This Cannabis Turnaround?
Shares shifted as Cresco Labs climbed 7.1% to $0.72 on August 6, with traders positioning ahead of second-quarter earnings — and the results delivered. The numbers show a company accelerating out of a loss cycle, but the stock still trades near its 52-week lows, raising a sharp question about whether the business improvement is real enough to hold.
• Revenue Jumped 15% in a Single Quarter, and the Company Turned Profitable
Cresco reported second-quarter 2026 revenue of $173 million, reflecting 15% sequential growth. That compares with first-quarter revenue of $151 million. More critically, Cresco posted net income of $15.4 million, compared with a net loss of $17 million in the first quarter and a $13.9 million loss during the second quarter of 2025. For shareholders, swinging from red to black ink in one quarter — while growing the top line by double digits — is the clearest signal yet that cost-cutting and new market launches are translating to actual cash returns.
• Wall Street Got Surprised — and the Stock Responded
The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of negative $0.02 by $0.06. That beat matters because it shows analysts had priced in continued losses. Gross profit totaled $87 million, while adjusted gross profit reached $89 million, representing an adjusted gross margin of 51.6% — a meaningful expansion from the prior quarter's 50.7%. For a cannabis company carrying $67 million in cash against a $311 million senior secured term loan and a $19 million mortgage , that widening profitability cushion is essential to managing its debt load.
• The CFO Is Leaving at a Critical Moment
Alongside its quarterly results, Cresco announced that Chief Financial Officer Sharon Schuler has decided to step down; the board has initiated a search for a permanent successor, while Mark Stortz will serve as interim CFO. Losing a finance chief during a profitability inflection point introduces execution risk. Investors will need to watch whether capital allocation discipline holds during the transition.
• Federal Rescheduling Hope Is Baked Into the Bull Case
Cresco cited federal cannabis rescheduling as a direct tailwind for its financial position and capital markets access. If rescheduling unlocks a U.S. stock exchange listing — the company is already spending on preparations for a potential U.S. exchange listing — Cresco could access a far deeper pool of institutional capital. But at a market cap of roughly $362 million , the stock is pricing in skepticism, not optimism. The gap between improving fundamentals and a beaten-down share price is where the real debate lies.